US2016339150A1PendingUtilityA1

Methods And Compositions For The Treatment Of Open And Closed Wound Spinal Cord Injuries

Assignee: CHILDREN'S MEDICAL CENTER CORPPriority: Apr 25, 2006Filed: Aug 5, 2016Published: Nov 24, 2016
Est. expiryApr 25, 2026(expired)· nominal 20-yr term from priority
A61P 9/14A61P 25/00A61L 2300/60A61K 35/12A61F 2/442A61L 31/16A61L 2300/802A61P 19/00A61L 31/14A61L 27/383A61F 2210/0004A61L 2300/606A61L 2300/412A61L 31/148A61L 27/58A61L 31/005A61L 31/146A61L 27/54A61L 2430/00A61L 2400/00A61L 27/18A61L 27/38A61L 27/50A61K 9/0085A61F 2/02A61L 27/56A61L 2300/64A61L 2430/38A61L 31/048A61L 27/26A61L 2300/414A61L 27/3834A61L 31/06A61L 2300/41A61L 27/3878
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Devices and methods for the treatment of open and closed wound spinal cord injuries are disclosed. For example, described herein are devices and methods for mitigating secondary injury to, and promoting recovery of, spinal cord primary injuries. More particularly, certain embodiments of the present invention are directed to polymeric mini-tubes that may be used for the treatment of spinal cord injuries. In addition, other embodiments are directed to polymeric “fill-in” bandages that may be used for the treatment of spinal cord injuries. For example, an erodible, or biodegradable, form of biocompatible polymer of the present invention is fabricated for surgical implantation into the site of the spinal cord injury.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A biodegradable and/or bioabsorbable polymeric tubular article suitable for treating a spinal cord injury in an animal, wherein the article comprises a biodegradable and/or bioabsorbable linear aliphatic polyester. 
     
     
         2 . The polymeric tubular article of  claim 1 , wherein the linear aliphatic polyester is a polyglycolide or a copolymer poly(glycolide-co-lactide). 
     
     
         3 . The polymeric tubular article of  claim 1 , comprising poly(lactic-co-glycolic acid). 
     
     
         4 . The polymeric tubular article of  claim 1 , comprising poly(lactic-co-glycolic acid)-polylysine. 
     
     
         5 . The polymeric tubular article of  claim 1 , comprising a blend of (1) poly(lactic-co-glycolic acid) and (2) a block copolymer of poly(lactic-co-glycolic acid)-polylysine. 
     
     
         6 . The polymeric tubular article of  claim 1 , comprising a 50:50 blend of (1) poly(lactic-co-glycolic acid) and (2) a block copolymer of poly(lactic-co-glycolic acid)-polylysine. 
     
     
         7 . The polymeric tubular article of  claim 6 , wherein the (1) poly(lactic-co-glycolic acid) is 75% poly(lactic-co-glycolic acid) and has an average molecular weight of Mn 40,000. 
     
     
         8 . The polymeric tubular article of  claim 6 , wherein the (2) block copolymer of poly(lactic-co-glycolic acid)-polylysine is 25% poly(lactic-co-glycolic acid)-polylysine copolymer and wherein the poly(lactic-co-glycolic acid) block has an average molecular weight of Mn ˜30,000 and the polylysine block has an average molecular weight of Mn ˜2,000. 
     
     
         9 . The polymeric tubular article of  claim 1 , wherein the article has an overall diameter of between about 0.1 microns and 10 millimeters. 
     
     
         10 . The polymeric tubular article of  claim 9 , wherein the article has an overall diameter of between about 50 and 175 microns. 
     
     
         11 . The polymeric tubular article of  claim 1 , comprising one or more medicinal agents deposited onto the article. 
     
     
         12 . The polymeric tubular article of  claim 1 , wherein the article comprises a monomer selected from the group consisting of a glycolide, lactide, dioxanone, caprolactone, trimethylene carbonate, ethylene glycol and lysine. 
     
     
         13 . The polymeric tubular article of  claim 1 , wherein the article is smaller than the length of the lesioned area of the spinal cord injury. 
     
     
         14 . The polymeric tubular article of  claim 1 , wherein the article is longer than the length of the lesioned area of the spinal cord injury. 
     
     
         15 . The polymeric tubular article of  claim 14 , wherein the article is approximately 1.5 times longer than the length of the lesioned area of the spinal cord injury. 
     
     
         16 . The polymeric tubular article of  claim 14 , wherein the article is about 1.2 to about 3 times longer than the length of the lesioned area of the spinal cord injury. 
     
     
         17 . The polymeric tubular article of  claim 1 , wherein the article is seeded with at least one medicinal agent. 
     
     
         18 . The polymeric tubular article of  claim 1 , wherein the article has a degradation rate of between 30 and about 60 days. 
     
     
         19 . The polymeric tubular article of  claim 1 , wherein the article comprises an electrically conducting polymer. 
     
     
         20 . The polymeric tubular article of  claim 18 , wherein the electrically conducting polymer is selected from the group consisting of polypyrrole polymer, polyaniline, polyacetyline, poly-p-phenylene, poly-p-phenylene-vinylene, polythiophene, and hemosin. 
     
     
         21 . The polymeric tubular article of  claim 2 , wherein the electrically conducting polymer is polypyrrole.

Join the waitlist — get patent alerts

Track US2016339150A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.